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Abstract
Background: Depression and anxiety are common co-morbid health problems in patients with type 2 diabetes.
Both depression and anxiety are associated with poor glycaemic control and increased risk of poor vascular
outcomes and higher mortality rates. Results of previous studies have shown that in clinical practice, treatment of
depression and anxiety is far from optimal as these symptoms are frequently overlooked and undertreated.
Methods/Design: This randomised controlled trial will examine the effectiveness of a disease management
programme treating symptoms of depression and anxiety in primary care patients with Type 2 diabetes. Patients
will be randomized on patient level in 1:1 ratio. Random block sizes of 2 and 4 are used. The disease management
programme consists of screening, stepped treatment and monitoring of symptoms (n = 80). This will be compared
to care as usual (n = 80).
Discussion: The disease management model for co-morbid depression and anxiety in primary care patients with
diabetes is expected to result in reduced symptoms of depression and anxiety, improved quality of life, reduced
diabetes specific distress and improved glyceamic control, compared to care as usual.
Trial Registration: Dutch Trial Register NTR2626
Keywords: diabetes, depression, anxiety, primary care, study protocol, randomised controlled trial, disease manage-
ment, stepped care, psychological intervention
Background
Diabetes mellitus is a common chronic disease affecting
more than 220 million patients worldwide, with approxi-
mately 90% having type 2 diabetes (DM2) [1]. Patients
with DM2 often have co-morbid affective symptoms
such as depression and anxiety. Results of recent studies
show that 10-30% of patients with DM2 suffer from
major depressive disorder or sub-threshold depression
[2-4], about 14% suffers from generalized anxiety disor-
der and up to 40% has an elevated level of anxiety
symptoms [5]. A meta-analysis of longitudinal studies
showed that diabetes patients are also at a 24%
increased risk of developing depression [6].
The high prevalence of depression and anxiety in
patients with DM2 has significant negative implications.
It is associated with poorer quality of life, impaired self-
care activities, higher health care costs, a higher risk for
the development of diabetes complications, and
increased mortality rates [7-13]. Despite these known
a d v e r s ee f f e c t sa n dt h eh i g hp r e v a l e n c eo fd e p r e s s i o n
and anxiety in DM2, and the fact that effective treat-
ments are available, there is a considerable underdetec-
tion and subsequent undertreatment of these conditions
[14,15]. Less than half of the depressed and/or anxious
patients with diabetes are recognised as such [14,15]. In
order to prevent the negative consequences of anxiety
and depression, early detection and enhanced treatment
thus seem crucial.
Meta-analyses have shown that treating depression
and anxiety in patients with DM2 results in reduced
psychological distress, but also in improved glyceamic
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Ismail et al. showed that psychological interventions
resulted in a significant better glyceamic haemoglobin,
with an absolute difference of 0.76% (or 76 mmol/mol)
[ 1 6 ] .As t u d yb yB o g n e re ta l .h a ss h o w nt h a tt h ea l l
cause mortality risk decreased when treating depression
in primary care patients with diabetes mellitus [7]. How-
ever, the study by Bogner has been criticized by Thombs
and Ziegelstein [18]. Given the high prevalence of
depression and anxiety in patients with DM2, and the
fact that these emotional problems are often overlooked
and undertreated, while effective treatments are avail-
able, current guidelines recommend screening for
depression and anxiety [19-21]. A recent randomised
controlled trial showed, however, that screening alone
did not improve depression outcomes in secondary dia-
betes care [22]. It seems crucial that screening efforts
should be embedded in a managed care approach for
depression/anxiety [23].
A large American randomised controlled trial, The
Pathways Study, tested the effectiveness of a collabora-
tive care approach consisting of screening, stepped care
intervention and collaboration between several health
professionals (multidisciplinary team) [24]. The colla-
borative care approach was more effective in reducing
depressive symptoms compared to usual care (z = 2.84,
P = 0.004 after 6 months). It was also cost-effective [25].
However, no effect on glyceamic control was found [24].
Another randomised controlled trial (n = 361) has been
conducted in the Netherlands in elderly primary care
patients with diabetes or COPD and co-morbid depres-
sion [26]. The intervention, provided at home by trained
nurses, was based on CBT principles and self-manage-
ment. While the intervention was effective in reducing
depressive symptoms (BDI improvement rate OR = 3.22
[1.31 - 7.89]), it was not cost-effective [27].
Most research focused on treating depression, and less
research has investigated a treatment for anxiety in
patients with DM2. The randomised controlled trials
investigating anxiety treatment in patients with diabetes
show less consistent results compared to the depression
trials; some studies showed a beneficial effect while
other did not [5,28].
In the present study, we therefore aim to test the
effectiveness of a disease management intervention. It
will be tested whether and to what extend the Disease
Management intervention for Co-morbid Depression
and Anxiety in patients with DM2(DiMaCoDeA-DM2)
can significantly reduce symptoms of depression and
anxiety. Using a randomised controlled trial design, we
will compare the new intervention to care as usual. Our
primary objective is to investigate the effectiveness of
the disease management approach on symptoms of
depression and/or anxiety. Our secondary objectives are
to investigate whether this approach results in improved
quality of life, reduced diabetes-specific emotional dis-
tress, improved lifestyle and self care behaviours, and
lower health care costs.
Methods/Design
Eligibility criteria
Eligible patients are type 2 diabetes mellitus patients,
aged 18 or over and with elevated depressive (PHQ-9
score ≥ 7) and/or anxiety symptoms (GAD-7 score ≥ 8;
see ‘assessment’ for more information about the PHQ-9
and GAD-7). Patients will be excluded if they currently
receive psychological treatment for their symptoms of
depression or anxiety, experience major psychiatric pro-
blems, such as schizophrenia and suicidal ideation, are
addicted to alcohol, drugs or gambling, are cognitively
impaired, or are unable to read or speak Dutch
sufficiently.
Study setting and sample recruitment
The study will be conducted in primary care practices
that are affiliated to a large primary care organisation
PoZoB (Praktijkondersteuning Zuidoost Brabant). Over
200 general practitioners and approximately 150 practise
nurses in a southern region of the Netherlands are asso-
ciated with PoZoB with approximately 12.000 patients
with DM2. The general practitioners, together with the
practice nurse are responsible for the primary care of
patients with chronic diseases such as DM2. Patients
with DM2 are seen by the practice nurse every three
months.
Patients with DM2 from the general practices that
agreed to participate will be screened for symptoms of
depression or anxiety with the PHQ-9 and GAD-7. Eli-
gible patients will be invited for an interview. During
this interview the baseline questionnaires will be admi-
nistered. When eligible patients agree to participate and
after they have given written informed consent, they will
be randomised into the intervention group or the care
as usual group.
Randomisation
Patients will be randomised on patient level in equal
ratio (1:1). Block randomisation will be used with block
sizes of 2 and 4. These block sizes are chosen to
enhance the chance that in each general practice
patients will be in both study conditions. An indepen-
dent researcher will generate a random sequence by
http://randomization.com and will fill envelopes with
the sheets describing the group allocation. These opaque
envelopes will be sealed and sequentially numbered by
the independent researcher. When a participant is
enrolled in the study, the person who enrols the partici-
pant will open the envelope and disclose the group
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until a participant is irreversibly registered.
Power
Assuming an a of 0.05 and a 1-b (power) of 0.90, 64
participants are needed in each condition to be able to
detect a moderate effect of 0.5 standard deviation on
t h eP H Q - 9a n dG A D - 7 .W ea n t i c i p a t ead r o po u to f
20% and therefore we will need to include 80 patients in
both groups.
Intervention
The DiMaCoDeA-DM2 intervention will continue for a
year and will consist of active screening, stepped care
treatment and monitoring of depression/anxiety (see
Figure 1).
Screening
All patients with diabetes in the collaborating general
practices will be screened for symptoms of depression
and anxiety using the PHQ-9 and GAD-7.
Stepped care
A stepped care model has been used to design the inter-
vention. This means that a basic treatment will be pro-
vided firstly, followed by intensified treatment when
needed, i.e. in case of non-remission or worsening of
symptoms. The DiMaCoDeA-DM2 stepped care treat-
ment will comprise of the following three steps. The
first step is psycho-education, which will consist of four
Figure 1 DiMaCoDeA Intervention.
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Page 3 of 630-minute lessons provided by trained psychologists. At
the end of the fourth lesson, the patient will fill out the
PHQ-9 and GAD-7. If the patient scores below the cut-
off score on both questionnaires (PHQ-9 < 7 and GAD-
7 < 8), the treatment will be stopped and the patient
will enter a phase in which symptom severity of depres-
sion/anxiety will be monitored. If the patient still suffers
from significant depression/anxiety, as indicated by
scores above the cut-off score, the patient will enter
step 2. In the second step the course ‘coping with
depression and anxiety’ will be offered to the patient.
T h ec o u r s ei sb a s e do nt h e“coping with depression”
course by Lewinson [29] and a “coping with anxiety”
course [30]. The course consists of a self-help book and
coaching. Coaching will be provided in the general prac-
tice office by trained psychologists and will take place
once a week for half an hour. Depending on the most
prominent complaints and on the patient’sp r e f e r e n c e
either the “coping with depression” course or the “cop-
ing with anxiety” course will be provided. A combina-
tion of the two courses is also possible. The course
takes 10 weeks to complete. Halfway through the course
and at the end of the course, the patient will fill out the
PHQ-9 and GAD-7. If during the course the symptoms
worsen, the patients will be offered the opportunity to
start with step 3, even though step 2 has not been fin-
ished. In step 3, the GP will offer the patients medica-
tion for their symptoms of depression and/or anxiety. If
medication is indicated, the general practitioner will
have contact with the patient to discuss side effects and
monitor the effect of the medication. Moreover, the
course will be elongated with a maximum of 6 sessions
in six months.
Monitoring
A crucial element of the intervention will be the fre-
quent monitoring of depression and anxiety. During the
DiMaCoDeA intervention, patients will fill out the
PHQ-9 and GAD-7 every three months. If the patient
has a score PHQ-9 ≥ 7 or GAD-7 ≥ 8, treatment will be
offered; if step 1 has been completed, step 2 will be
offered, and if step 2 has been completed, step 3 will be
offered.
Control group
The control group will receive care as usual. During the
assessments (see below) the participants will fill out the
PHQ-9 and GAD-7. If a patient in the control group
has two consecutive PHQ-9 scores ≥ 15 or two consecu-
tive GAD-7 scores ≥ 15, the general practitioner will be
notified.
Assessments
A l lp a r t i c i p a n t sw i l lf i l lo u tq u e s t i o n n a i r e sa t7t i m e
points: at baseline, 3, 6, 9, 12, 18 and 24 months. The
primary outcomes are symptoms of depression and
anxiety as measured by the PHQ-9 and GAD-7 [31,32].
The PHQ-9 is a screening tool that has nine items that
correspond to the nine DSM-IV criteria of depression
[31]. With the PHQ-9 the patients are asked how often
in the last two weeks they were bothered by nine pro-
blems such as “ Little interest or pleasure in doing
things”. Each item can be scored from 0 ("not at all”)t o
3 ("nearly every day”). The total score on the PHQ-9
ranges from 0 to 27. This score indicates the severity of
the depressive symptoms; the higher the score, the more
severe [31]. A study with primary care patients with dia-
betes found an optimal cut off score for depression
screening of 7 [33]. The cut-off point of 7 on the PHQ-
9, was the most optimal cut off score to predict major
depressive disorder measured by a diagnostic interview
[33]. Therefore the cut-off of PHQ-9 ≥ 7 will be used in
this study. The GAD-7 will be used to assess anxiety
symptoms. This questionnaire has been developed to
assess generalized anxiety disorder, but can also be used
as a screener for several anxiety disorders [32]. A cut-off
score of 8 has been found to be the most optimal cut-
off score, when used as a screener for several anxiety
disorders [32]. Therefore, patients with a score GAD-7
≥ 8 are considered as having significant anxiety
symptoms.
During the baseline interview the Mini International
Neuropsychiatric Interview (MINI) is administered to
assess major depression and general anxiety disorder.
The MINI will not be used as a selection criterion.
Secondary outcomes are quality of life, health status,
diabetes specific distress, self-management, medication
adherence, and cost-effectiveness. Baseline and 12, 24
months HbA1c will be obtained from the patients’
charts, to evaluate the effect on blood glucose. Further-
more, we will gather data regarding demographics (age,
gender, marital status, and education), exercise (mea-
sured with SQUASH [34]), smoking and alcohol use,
body mass index, psychiatric history, sleep impairment,
and Type D (distressed) personality (DS-14 [35]). Type
D is a personality type that is characterised by negative
affectivity and social inhibition. Research on Type D
personality has been mostly conducted in cardiac
patients. In this population, it has been found that per-
sons with Type D personality have a three-fold risk of
adverse cardiac outcomes [36].
Blinding
The nature of the study does not allow blinding of
patients, therapists and researchers.
Statistical analyses
T h ed a t aw i l lb ea n a l y s e du s i n gi n t e n t i o nt ot r e a t
approach. This means that participants are analysed in
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participant did not start the intervention or did not
complete the intervention. To test whether the interven-
tion group differs from the control group in terms of
demographical and clinical data, T-tests and Chi-square
analyses will be used. To test the efficacy of the inter-
vention in achieving favourable outcomes, ANCOVA’s
will be conducted. The analyses will be adjusted for the
possible confounding variables age and sex.
Ethics
The study has been approved by the medical ethical
committee of the Sint Elisabeth Hospital, the Nether-
lands NL3363.008.10. The trial is registered in the
Dutch Trial Register NTR2626.
Discussion
This randomised controlled trial will test the effective-
ness of a disease management model of anxiety and
depression symptoms in Dutch patients with DM2 who
are treated in primary care. We expect that the managed
care intervention will contribute to enhanced treatment
of depression/anxiety and a reduction of symptoms of
anxiety and depression. We hypothesize that the inter-
vention will also result in improved quality of life,
reduced diabetes specific distress, better glycaemic con-
trol and lower health care cost. A first strength of the
intervention is that it will largely take place in the gen-
eral practice office. This will make it easier for patients
to participate, because they do not have to travel to spe-
cialized mental health care institution. A second
strength of the intervention is the stepped care
approach. This means that the patient receives as much
treatment as needed. Providing only the most intensive
treatment to specific patients, will reduce the costs of
the intervention. A third strength of the intervention is
the monitoring of symptoms of anxiety and depression.
It is known that anxiety and depressive symptoms often
do recur, but are overlooked. It is therefore important
to monitor patients to detect recurring anxiety and
depressive symptoms and offer treatment if needed. A
fourth strength is the RCT design. By randomising
patients, possible confounders will be distributed ran-
domly over the groups. Thereby, a possible different
o u t c o m eb e t w e e nt h et w og r o u p si sm o s tl i k e l yt ob e
attributed to the intervention.
A possible limitation in the design is that the GP will
be informed when a patient of the control group has
two consecutive high scores. As a consequence the GP
may start an intervention and this might interfere with
care as usual. However, several studies have shown that
focusing on detection, does not automatically lead to
improved psychological care [22,23,37].
In conclusion, this trial will compare a disease man-
agement model with usual care. This model will
improve detection of symptoms of depression and anxi-
e t ya n dw i l lp r o v i d ea ne a s i l ya c c e s s i b l es e r v i c et o
patients to improve their well-being. In the long-term
this model might result in less diabetes complications
and reduced mortality rate.
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